Af­ter an EU ap­proval, As­traZeneca and Sanofi's RSV an­ti­body seeks an FDA thumbs-up in Q3

The FDA is now re­view­ing As­traZeneca’s nir­se­vimab, a po­ten­tial an­ti­body drug de­signed in col­lab­o­ra­tion with Sanofi for res­pi­ra­to­ry syn­cy­tial virus (RSV) that won ap­proval in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER